JP2024504225A5 - - Google Patents
Info
- Publication number
- JP2024504225A5 JP2024504225A5 JP2023523609A JP2023523609A JP2024504225A5 JP 2024504225 A5 JP2024504225 A5 JP 2024504225A5 JP 2023523609 A JP2023523609 A JP 2023523609A JP 2023523609 A JP2023523609 A JP 2023523609A JP 2024504225 A5 JP2024504225 A5 JP 2024504225A5
- Authority
- JP
- Japan
- Prior art keywords
- covid
- cov
- sars
- antiviral composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091915P | 2020-10-14 | 2020-10-14 | |
| US63/091,915 | 2020-10-14 | ||
| US202063107429P | 2020-10-29 | 2020-10-29 | |
| US63/107,429 | 2020-10-29 | ||
| US202163139302P | 2021-01-19 | 2021-01-19 | |
| US202163139306P | 2021-01-19 | 2021-01-19 | |
| US63/139,302 | 2021-01-19 | ||
| US63/139,306 | 2021-01-19 | ||
| US202163144606P | 2021-02-02 | 2021-02-02 | |
| US63/144,606 | 2021-02-02 | ||
| US202163145453P | 2021-02-03 | 2021-02-03 | |
| US63/145,453 | 2021-02-03 | ||
| PCT/US2021/054789 WO2022081711A1 (en) | 2020-10-14 | 2021-10-13 | Lipopeptide fusion inhibitors as sars-cov-2 antivirals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504225A JP2024504225A (ja) | 2024-01-31 |
| JP2024504225A5 true JP2024504225A5 (https=) | 2024-10-18 |
Family
ID=81208578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523609A Pending JP2024504225A (ja) | 2020-10-14 | 2021-10-13 | Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としてのリポペプチド融合阻害物質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240226304A1 (https=) |
| EP (1) | EP4228673A4 (https=) |
| JP (1) | JP2024504225A (https=) |
| KR (1) | KR20240038643A (https=) |
| CA (1) | CA3195563A1 (https=) |
| IL (1) | IL302066A (https=) |
| TW (1) | TW202229316A (https=) |
| WO (1) | WO2022081711A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022159372A1 (en) * | 2021-01-22 | 2022-07-28 | Decoy Therapeutics, Inc. | Methods and compositions for treating infections |
| CN118354791A (zh) * | 2021-10-22 | 2024-07-16 | 威斯康星校友研究基金会 | 抑制导致新冠肺炎疾病的病毒sars-cov-2感染的肽 |
| WO2024016011A2 (en) * | 2022-07-15 | 2024-01-18 | The Trustees Of Columbia University In The City Of New York | Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses |
| CN115746148B (zh) * | 2022-10-14 | 2023-09-12 | 中国医学科学院病原生物学研究所 | 具有冠状病毒rbd和膜融合抑制多肽的蛋白质及其作为冠状病毒抑制剂的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2247606B1 (en) * | 2008-01-23 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of viral infections |
| WO2015171924A2 (en) * | 2014-05-07 | 2015-11-12 | Cornell University | Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them |
| JP2021512596A (ja) * | 2018-01-31 | 2021-05-20 | ヴェラ セラピューティクス エルエルシー | Ａｄａｍ９生物活性を阻害するための方法および組成物 |
| CN111732637B (zh) * | 2020-05-25 | 2022-03-01 | 上海交通大学 | 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用 |
| CN111560054A (zh) * | 2020-06-16 | 2020-08-21 | 哈尔滨吉象隆生物技术有限公司 | 抑制新型冠状病毒感染的多肽及其筛选方法 |
-
2021
- 2021-10-13 WO PCT/US2021/054789 patent/WO2022081711A1/en not_active Ceased
- 2021-10-13 JP JP2023523609A patent/JP2024504225A/ja active Pending
- 2021-10-13 CA CA3195563A patent/CA3195563A1/en active Pending
- 2021-10-13 KR KR1020237016292A patent/KR20240038643A/ko active Pending
- 2021-10-13 IL IL302066A patent/IL302066A/en unknown
- 2021-10-13 US US18/249,058 patent/US20240226304A1/en active Pending
- 2021-10-13 EP EP21880997.8A patent/EP4228673A4/en active Pending
- 2021-10-14 TW TW110138190A patent/TW202229316A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504225A5 (https=) | ||
| JP2024170583A5 (https=) | ||
| JP2002511385A5 (https=) | ||
| JP2014515373A5 (https=) | ||
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2002528502A5 (https=) | ||
| JP2023520323A5 (https=) | ||
| WO2021047648A1 (en) | New peptides | |
| JP2023524911A5 (https=) | ||
| Harfouch et al. | Therapeutic approaches for COVID 19: Challenges and successes | |
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| JP2023520929A5 (https=) | ||
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| JP2024543259A5 (https=) | ||
| CN111320662B (zh) | 一类n-苄基取代的二脒那秦衍生物及其药物用途 | |
| JP2024546179A5 (https=) | ||
| WO2022123323A1 (en) | A pharmaceutical composition of artesunate and mefloquine and method thereof | |
| WO2021049980A1 (ru) | Новые составы для лечения и профилактики вирусных заболеваний | |
| CN115867288A (zh) | 用于治疗呼吸系统病症的组合物 | |
| WO2021242751A1 (en) | Compositions and methods for treating sars-cov-2 | |
| JP5765650B2 (ja) | インフルエンザウイルス感染症の予防および／または治療剤 | |
| ES3002532T3 (en) | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections | |
| US20240358659A1 (en) | Uses of Propranolol for Managing Viral Infections | |
| RU2746692C1 (ru) | Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний |